Xenohelix
Incheon, South Korea · Founded 2019
- Headquarters
- Incheon
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- xenohelix.com
- Last Round
- SeedSep 2019
- Rounds
- 1
About
Xenohelix (제노헬릭스) is a South Korean biotech company specializing in small RNA (sRNA) platform technology for molecular diagnostics and research. The company develops ultra-sensitive RNA detection platforms including XENOPURE for high-purity RNA extraction and XENO-Q for single-base-pair precision diagnostics, targeting conditions such as Parkinson's disease and fatty liver disease. Its technology enables non-invasive, blood-based early diagnosis as an alternative to expensive conventional tests, and the company also offers cosmetic products derived from natural exosomes.
Summary
Xenohelix is a Biotech company based in Incheon, South Korea, founded in 2019. Its most recent funding was a Seed round in Sep 2019. Investors include KB Investment and Partners Investment.
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Funding History
Sep 2019
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company